ArticleBMC microbiology2026
Molecular evolution and mechanisms underlying extremely high-level carbapenem resistance in the emerging CRPA clone ST1976.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCarbapenem-resistant Pseudomonas aeruginosa (CRPA) represents a critical threat to clinical therapy, yet the genetic basis underlying extremely high-level carbapenem resistance remains poorly understood. An emerging CRPA clone, ST1976, has recently been identified in China with unusually high meropenem MICs.
methodsST1976 CRPA isolates collected between 2018 and 2022 were subjected to antimicrobial susceptibility testing, whole-genome and Nanopore sequencing, and bioinformatic analyses. Cloning assays and sodium mercaptoacetic acid inhibition tests were performed to investigate the molecular basis of carbapenem resistance.
resultsDuring the study period from 2018 to 2022, ST1976 was one of the predominant CRPA clones in Henan Province, exhibiting a significantly increasing trend and carrying significantly more resistance and virulence genes than other major regional clones. Phylogenomic analyses suggested that ST1976 emerged approximately two decades ago and may serve as a regional reservoir of bla
conclusionsST1976 represents an emerging high-risk CRPA clone characterized by convergent plasmid- and chromosome-mediated mechanisms driving extremely high-level carbapenem resistance, highlighting the need for enhanced surveillance and targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.